Evidence map

ArticleClinical drug investigation2025

Cost-Effectiveness of Adding Dapagliflozin and Empagliflozin to Standard Treatment for Diabetic Kidney Disease in China.

Tingting Qiu et al.PubMed ↗Publisher ↗

No numbers read from the abstract.

1 paper cites it

2025
2026
this paperpooled itcites it
Full record →Abstract, authors, funding and every citing paper · PMID 40658333